Related Experiment Video
Updated: Aug 28, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Extracellular vesicles versus synthetic nanoparticles for drug delivery
Kenneth W Witwer1,2, Joy Wolfram3,4,5
1Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
None:
Cell-released biological nanoparticles, including extracellular vesicles (EVs), are emerging drug carriers with high complexity. EV-based drug delivery has the potential to efficiently exploit intrinsic mechanisms for molecular transport in the body. Integrating the expanding knowledge of EV biology and manufacturing with clinical insights from synthetic nanoparticles is likely to substantially advance the field of drug delivery.

